In the rapidly evolving landscape of biopharmaceuticals, the role of Contract Development and Manufacturing Organizations (CDMOs) has become increasingly vital. CDMOs play a crucial part in supporting the development and production of complex biopharmaceutical products. Here we will explore the emerging key requirements in CDMO projects for biopharmaceuticals; shedding light on the evolving needs of customers and the capabilities CDMOs must possess to meet these demands.
Further insights are available in our latest expert interviews:
1. Trends & Requirements in CDMO Projects
2. ProBioGen´s Answer to Customer Requirements
Customer Expectations and New Trends in CDMO Projects
Diversification: Multiple and more complex molecules and projects
Historically, biopharmaceutical CDMO projects focused on proteins and „simple“ antibodies. In the last few years, there has been a shift towards more complex molecule formats. Further, clients are approaching CDMOs at earlier stages of development, when they are still evaluating multiple product candidates. All this leads to a higher level of complexity in CDMO projects.
Quality: A Heartfelt Commitment
The high quality of biopharmaceutical products is paramount. GMP manufacturing and supply of materials for toxicology studies require strict adherence to quality standards. An unshakable commitment to maintaining superior product quality should be at the heart of the development and manufacturing process. This commitment should start with the design of the manufacturing process and extend to every step, from the selection of raw materials to final product testing.
Time Pressure: Accelerated, yet reliable timelines
With overall cut development times, customer expect not only shorter but also reliable timelines. Time pressures in biopharmaceutical CDMO projects are driven primarily by fierce market competition, regulatory requirements, and the need to maintain patent exclusivity. Customers aim to bring drugs to market quickly to minimize development costs, meet patient needs and satisfy investor expectations.
Capabilities Required from CDMO Partners
With that, the expectations and demands on CDMOs are increasing and are not likely to level off anytime soon. As a CDMO, it is crucial to recognize and to address these demands and trends in order to provide customers the best possible and comprehensive support.
Customers require experienced CDMOs to tackle such diverse and challenging molecule formats through innovation and efficiency
Integrated-Services: Tackling Time Pressure with end-to-end offering
CDMOs should provide a one-stop shop from cell line development to manufacturing, with the ability to seamlessly integrate multiple activities. This holistic approach, supported by in-house analytics and bioassay development, allows for parallel processes, efficient project execution with data-driven decision-making. This integrated methodology is the only way for a CDMO to shorten the overall timeline.
Scientific Excellence: Assure product quality and adopt to challenges
A CDMO must have a thorough understand of the client’s product and work to realize its full potential.
Besides the scientific know-how of the teams, CDMOs should commit to analytical technological expertise, seamlessly integrated into cell line development, process development and production, and leverage scientific excellence to develop a deep understanding of product specific challenges. This scientific expertise also extends to the unique properties of the product. When faced with such challenges, scientifically-led project management is essential for success, as it goes beyond molecular and cell biology.
Furhter, a good partner should process proprietary technology in gene editing, glycan modification and media platforms to allow them to tailor processes to individual product needs and produce high-quality products. An emphasis on post-translational modifications beyond titer levels is also needed to improve overall product quality.
CDMOs with experience working with analogous molecules are well positioned to anticipate and overcome hurdles but unforeseen challenges can always occur. Weather such challenges are unexpected reactions, novel peaks in chromatograms or others - CDMOs must be flexible and able to adapt to the project-specific challenges. Through anticipation and agilely responding to unforeseen challenges, CDMOs can and must maintain projects on schedule and ensure that milestones are reached.
Customer centricity: Partnerships as key to customer success
A close relationship with the client is key to success. It allows for better collaboration and a deeper understanding of the client’s needs. CDMOs should strive to develop a collaborative relationship with their clients that goes beyond a simple business transactions and leads to better results. By investing in a collaborative relationship with the client, characterized by open communication and a willingness to go an extra mile, CDMOs can create an atmosphere of trust and mutual growth.
This collaborative approach further allows for parallel processing and efficient decision-making. To be successful, a reliable CDMO must be able to expedite the development process while also delivering high quality within the agreed-upon timelines.
Conclusion
As the biopharmaceutical industry continues to advance, CDMOs play an indispensable role in meeting the evolving needs of customers. The demand for complex molecules, accelerated timelines, and high-quality products have forced CDMOs to adapt and enhance their capabilities. By offering an integrated end-to-end process, scientific excellence, experience, flexibility, and a customer-centric approach, CDMOs can ensure successful project outcomes in the dynamic landscape of biopharmaceutical development and manufacturing.
At ProBioGen, our mission is to facilitate the development of tomorrow's medicines with our knowledge and unique technologies today - even for diseases that are not yet curable.
Our values – innovation, passion, partnership, solution-oriented thinking, and being fearless – are not mere words. They are the core of our commitment to shape the future of biopharmaceuticals. As we understand and respond to the evolving trends and requirements, we ensure that we stand by our clients as trusted partners. Our integrated processes, scientific excellence, and commitment to deliver high-quality products reflect our dedication to propel biopharmaceuticals forward and ultimately contribute to the enhancement of global healthcare.
Want to learn more about our Services for Proteins an Antibodies? Learn more by clicking on the following Button:
Interested in further insights about trends and requirements in CDMO projects for biopharmaceuticals? Then you have to check in on our latest expert interviews!
PART 1: Trends & Challenges in CDMO-Projects
PART 2: ProBioGen Answer to Customer Requirements
